Definitive Healthcare Corp. (NASDAQ:DH) Receives Consensus Recommendation of “Hold” from Brokerages

Definitive Healthcare Corp. (NASDAQ:DH) has received a consensus recommendation of “Hold” from the eleven brokerages that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $5.72.

A number of equities research analysts recently commented on DH shares. Barclays reissued an “underweight” rating and set a $4.00 target price on shares of Definitive Healthcare in a research report on Monday, January 13th. Needham & Company LLC restated a “hold” rating on shares of Definitive Healthcare in a research note on Thursday, January 16th. Finally, Stephens started coverage on Definitive Healthcare in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.00 price target on the stock.

Definitive Healthcare Stock Down 4.3 %

NASDAQ:DH opened at $4.62 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49. The firm has a market cap of $533.72 million, a PE ratio of -1.49, a price-to-earnings-growth ratio of 3.54 and a beta of 1.41. The company has a 50-day moving average of $4.36 and a 200 day moving average of $4.46. Definitive Healthcare has a 1-year low of $3.19 and a 1-year high of $10.62.

Definitive Healthcare (NASDAQ:DH) last posted its earnings results on Thursday, November 7th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.03). The company had revenue of $62.70 million for the quarter, compared to analysts’ expectations of $61.66 million. Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. During the same quarter in the prior year, the company earned $0.01 EPS. As a group, research analysts anticipate that Definitive Healthcare will post 0.15 EPS for the current fiscal year.

Insider Transactions at Definitive Healthcare

In related news, insider William Moschella sold 45,000 shares of Definitive Healthcare stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $4.70, for a total transaction of $211,500.00. Following the completion of the transaction, the insider now directly owns 433,830 shares in the company, valued at approximately $2,039,001. This trade represents a 9.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 14.84% of the company’s stock.

Hedge Funds Weigh In On Definitive Healthcare

Institutional investors have recently made changes to their positions in the company. Rhumbline Advisers boosted its position in Definitive Healthcare by 19.7% during the second quarter. Rhumbline Advisers now owns 83,751 shares of the company’s stock worth $457,000 after purchasing an additional 13,764 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Definitive Healthcare by 50.5% during the 2nd quarter. Renaissance Technologies LLC now owns 28,900 shares of the company’s stock valued at $158,000 after buying an additional 9,700 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in Definitive Healthcare in the 2nd quarter valued at $127,000. Canada Pension Plan Investment Board purchased a new stake in Definitive Healthcare in the 2nd quarter worth $109,000. Finally, Marshall Wace LLP acquired a new position in Definitive Healthcare during the second quarter worth $1,535,000. 98.67% of the stock is owned by hedge funds and other institutional investors.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.